15. Remicade

Remicade's most recent biosimilar challenger was approved in December. (Johnson & Johnson)

Company: Johnson & Johnson
2019 sales: $5.03 billion
Projected 2026 sales: $1.39 billion
Projected CAGR: -17%
Used for: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease

Once a giant in the immunology field, sales of Johnson & Johnson's Remicade have slipped precipitously after years of biosimilar competition. The future doesn't look much brighter, unfortunately, and J&J is looking for winners in its portfolio to make up the gap. 

Remicade hit $5.03 billion in sales in 2019, and it could see a catastrophic 17% decline in sales through 2026, according to Evaluate Pharma. That forecast would put Remicade's 2026 sales at roughly $1.36 billion. 

The wheels have already come off Remicade's sales after more than two years of biosimilar pressure. In the second quarter, the drug's sales dipped by 14% from the same period last year at $935 million. 

RELATED: Bolstered by immunology and oncology, J&J's pharma business holds up under COVID-19 pressure

15. Remicade